Know Labs appeals NYSE delisting as it shifts to OTC market

SEATTLE - Know Labs, Inc., a company specializing in radio frequency dielectric spectroscopy technology, has filed an appeal following the NYSE American’s decision to begin delisting proceedings against the firm. The delisting is due to the company’s stock price falling below the minimum bid price requirement. According to InvestingPro data, the stock has experienced significant decline across multiple timeframes, with particularly sharp drops over the past week, month, and three months. Trading of Know Labs’ stock, previously under the ticker NYSE American: KNW, has been suspended and will now continue on the over-the-counter (OTC) market with the symbol OTC Markets: KNWN, effective January 29, 2025.

The NYSE American has determined that Know Labs is unsuitable for listing under Section 1003(f)(v) of its Company Guide, prompting the company to undertake certain actions to regain compliance while its appeal is under review by the Listings Qualifications Panel.

Despite this setback, Know Labs’ CEO, Ron Erickson, expressed optimism about the company’s future, citing the recent initiation of a licensing program for its platform technology, peer-reviewed recognition, overhead reduction, and continued advancement of proprietary technology. Erickson reaffirmed the company’s commitment to its business plan and its focus on delivering non-invasive diagnostic products to the market, starting with a blood glucose monitor that is awaiting FDA clearance.

Know Labs’ technology uses radio frequency spectroscopy to identify unique molecular signatures, with potential applications in various wearable, mobile, or bench-top devices. The company’s forward-looking statements, as outlined in their Safe Harbor Statement, reflect intentions and expectations regarding future financing, trends, growth, operating strategies, and product performance.

This article is based on a press release statement from Know Labs, Inc. The company has cautioned investors that forward-looking statements involve risks and uncertainties and that actual results may differ materially from those projected. Know Labs has emphasized that it does not intend to update any forward-looking statements unless required by law.

In other recent news, a series of noteworthy developments have occurred at Know Labs, Inc. The company has extended the expiration dates of several warrant agreements with Clayton Struve, affecting four sets of warrants originally set to expire between 2025 and 2026, now extended to corresponding dates in 2030. In addition, Know Labs has amended the terms of its senior secured convertible redeemable notes, extending their maturity by one year to September 30, 2025.

Simultaneously, the company has announced a registered direct offering priced at-the-market under NYSE American rules, with gross proceeds expected to be $300,000 before deductions. This offering consists of a share of stock and a corresponding warrant, each priced at $0.24.

Furthermore, Know Labs has been granted an extension by NYSE American LLC to regain compliance with the exchange’s listing standards, allowing it until March 27, 2026, to meet the necessary criteria. These recent developments reflect the ongoing strategic financial and operational maneuvers within the company.

While the reasons for these extensions and amendments were not disclosed, they suggest a long-term commitment from both the company and Clayton Struve. These actions may indicate the company’s current liquidity status and its plans for future capital management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.